Current Editions
Hub 101: Taiwan biotech looks to level up
Four companies show how Taiwan is combining global ambition, local capital, and technology strengths to build a biotech hub
Editor's Commentary
Regulation
EMA’s CHMP backs two orphan drugs, rebuffs FDA-approved NPC therapy
Among eight positive opinions, Minoryx’s cALD therapy wins backing after a 2024 rejection
Finance
Scribe extends run of strong biotech IPO debuts: Public Equity Report
Plus: PIPEs for reverse mergers as Mentari, Freenome reach NASDAQ; Dyne’s follow-on; and more
Management Tracks
Song among trio of new partners at Venrock
Plus: Moves at Roche, Sanofi and more
BioCentury ISSN 1097-7201